Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
Abstract Recent breakthroughs in targeted therapy and immunotherapy have revolutionized the treatment of lung cancer, the leading cause of cancer-related deaths in the United States and worldwide. Here we provide an overview of recent progress in immune checkpoint blockade therapy for treatment of n...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-11-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4990-5 |
id |
doaj-25defed324714f45b39b0b4fa38b3554 |
---|---|
record_format |
Article |
spelling |
doaj-25defed324714f45b39b0b4fa38b35542020-11-25T02:21:22ZengBMCBMC Cancer1471-24072018-11-0118111010.1186/s12885-018-4990-5Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistanceXingxiang Pu0Lin Wu1Dan Su2Weimin Mao3Bingliang Fang4Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/the affiliated Cancer Hospital of Xiangya school of Medicine, Central South UniversityDepartment of Pathology, Zhejiang Cancer HospitalDepartment of Thoracic Surgery, Zhejiang Cancer HospitalDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer CenterAbstract Recent breakthroughs in targeted therapy and immunotherapy have revolutionized the treatment of lung cancer, the leading cause of cancer-related deaths in the United States and worldwide. Here we provide an overview of recent progress in immune checkpoint blockade therapy for treatment of non-small cell lung cancer (NSCLC), and discuss biomarkers associated with the treatment responses, mechanisms underlying resistance and strategies to overcome resistance. The success of immune checkpoint blockade therapies is driven by immunogenicity of tumor cells, which is associated with mutation burden and neoantigen burden in cancers. Lymphocyte infiltration in cancer tissues and interferon-γ–induced PD-L1 expression in tumor microenvironments may serve as surrogate biomarkers for adaptive immune resistance and likelihood of responses to immune checkpoint blockade therapy. In contrast, weak immunogenicity of, and/or impaired antigen presentation in, tumor cells are primary causes of resistance to these therapies. Thus, approaches that increase immunogenicity of cancer cells and/or enhance immune cell recruitment to cancer sites will likely overcome resistance to immunotherapy.http://link.springer.com/article/10.1186/s12885-018-4990-5Immune checkpoint inhibitorsPD-1PD-L1Predictive biomarkersResistance |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xingxiang Pu Lin Wu Dan Su Weimin Mao Bingliang Fang |
spellingShingle |
Xingxiang Pu Lin Wu Dan Su Weimin Mao Bingliang Fang Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance BMC Cancer Immune checkpoint inhibitors PD-1 PD-L1 Predictive biomarkers Resistance |
author_facet |
Xingxiang Pu Lin Wu Dan Su Weimin Mao Bingliang Fang |
author_sort |
Xingxiang Pu |
title |
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance |
title_short |
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance |
title_full |
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance |
title_fullStr |
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance |
title_full_unstemmed |
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance |
title_sort |
immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2018-11-01 |
description |
Abstract Recent breakthroughs in targeted therapy and immunotherapy have revolutionized the treatment of lung cancer, the leading cause of cancer-related deaths in the United States and worldwide. Here we provide an overview of recent progress in immune checkpoint blockade therapy for treatment of non-small cell lung cancer (NSCLC), and discuss biomarkers associated with the treatment responses, mechanisms underlying resistance and strategies to overcome resistance. The success of immune checkpoint blockade therapies is driven by immunogenicity of tumor cells, which is associated with mutation burden and neoantigen burden in cancers. Lymphocyte infiltration in cancer tissues and interferon-γ–induced PD-L1 expression in tumor microenvironments may serve as surrogate biomarkers for adaptive immune resistance and likelihood of responses to immune checkpoint blockade therapy. In contrast, weak immunogenicity of, and/or impaired antigen presentation in, tumor cells are primary causes of resistance to these therapies. Thus, approaches that increase immunogenicity of cancer cells and/or enhance immune cell recruitment to cancer sites will likely overcome resistance to immunotherapy. |
topic |
Immune checkpoint inhibitors PD-1 PD-L1 Predictive biomarkers Resistance |
url |
http://link.springer.com/article/10.1186/s12885-018-4990-5 |
work_keys_str_mv |
AT xingxiangpu immunotherapyfornonsmallcelllungcancersbiomarkersforpredictingresponsesandstrategiestoovercomeresistance AT linwu immunotherapyfornonsmallcelllungcancersbiomarkersforpredictingresponsesandstrategiestoovercomeresistance AT dansu immunotherapyfornonsmallcelllungcancersbiomarkersforpredictingresponsesandstrategiestoovercomeresistance AT weiminmao immunotherapyfornonsmallcelllungcancersbiomarkersforpredictingresponsesandstrategiestoovercomeresistance AT bingliangfang immunotherapyfornonsmallcelllungcancersbiomarkersforpredictingresponsesandstrategiestoovercomeresistance |
_version_ |
1724866746775502848 |